Targeted therapies against tumors with mutant p53 mainly focus on 1) reactivation or restoration of mutant p53 to wild-type p53 functions, 2) promoting degradation, 3) inducing synthetic lethality, 4) inhibiting its gain-of-function-associated interactors or pathways, 5) immunotherapies, and 6) gene therapies with vectors to incorporate wild-type p53 gene into tumor cells (Figure 6; Table 2). The gene discussed is TP53; the disease is neoplasm.